2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of <i>N</i>-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent <i>pan</i>-Src Kinase Inhibitor
作者:Jagabandhu Das、Ping Chen、Derek Norris、Ramesh Padmanabha、James Lin、Robert V. Moquin、Zhongqi Shen、Lynda S. Cook、Arthur M. Doweyko、Sidney Pitt、Suhong Pang、Ding Ren Shen、Qiong Fang、Henry F. de Fex、Kim W. McIntyre、David J. Shuster、Kathleen M. Gillooly、Kamelia Behnia、Gary L. Schieven、John Wityak、Joel C. Barrish
DOI:10.1021/jm060727j
日期:2006.11.1
2-aminothiazole (1) was discovered as a novel Src family kinase inhibitor template through screening of our internal compound collection. Optimization through successive structure-activity relationship iterations identified analogs 2 (Dasatinib, BMS-354825) and 12m as pan-Src inhibitors with nanomolar to subnanomolar potencies in biochemical and cellular assays. Molecular modeling was used to construct
通过筛选我们的内部化合物集合,发现了2-氨基噻唑(1)作为一种新型Src家族激酶抑制剂模板。通过连续的结构-活性关系迭代进行的优化确定了类似物2(Dasatinib,BMS-354825)和12m是在生化和细胞分析中具有纳摩尔至亚纳摩尔浓度的pan-Src抑制剂。分子模型被用来构建推定的结合模型,以抑制这类化合物对Lck的抑制作用。该模型提出的关键氢键相互作用的框架与随后公布的与结构相似的Abl激酶结合的2的晶体结构一致。此类抑制剂的口服药效为12m,可在小鼠体内体外抑制促炎细胞因子IL-2(ED50约为5 mg / kg),并在急性小鼠炎症模型中降低TNF水平(LPS抑制90%) LPS给药前2小时以60 mg / kg口服给药时,TNF-α诱导的TNFα产生)。当每天两次以0.3和3 mg / kg口服给药时,在已确诊疾病的大鼠的慢性佐剂性关节炎模型中进一步证明了12m的口服功效。达沙